AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.6000
0.0000 (0.00%)
As of 10:03AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.6000
Open2.6100
Bid2.6300 x 1400
Ask2.6800 x 800
Day's Range2.6000 - 2.6900
52 Week Range1.0000 - 3.7500
Volume36,325
Avg. Volume92,035
Market Cap51.566M
Beta (3Y Monthly)3.07
PE Ratio (TTM)N/A
EPS (TTM)-0.8770
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.84
Trade prices are not sourced from all markets
  • GlobeNewswire2 hours ago

    AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has now surpassed the 50% enrollment target in its ongoing Phase II OPTION study of MS1819-SD for exocrine pancreatic insufficiency in patients with cystic fibrosis (CF). The Phase II multi-center OPTION study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head comparison against the current porcine pancreatic enzyme replacement therapy (PERT) standard of care for exocrine pancreatic insufficiency in CF patients.  Planned enrollment is expected to include approximately 30 CF patients, with top-line results expected in Summer 2019.

  • Zacks Small Cap Research12 days ago

    AZRX: CF Study Up and Enrolling; Target to $8

    Highlights for the year and to date include participation in investment conferences, the addition of Dr. James Pennington as CMO, presentation of favorable trial data from chronic pancreatitis patients, the launch of the cystic fibrosis trial, and acquisition of rights from Protea and Mayoly. Research and development expenses were up 108% compared to the prior year period.

  • GlobeNewswire21 days ago

    Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights

    AzurRx materially expands global commercial rights, with full development control of MS1819 programMayoly retains certain commercial rights, while obtaining a sizeable equity.

  • GlobeNewswirelast month

    AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference

    NEW YORK, March 18, 2019 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies.

  • GlobeNewswirelast month

    AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)

    The company’s management will provide an overview of the Company's business during the live presentation and will be participating in one-on-one meetings with investors who are registered to attend the conference.

  • GlobeNewswirelast month

    AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced a poster presentation at the 2019 Annual Meeting of the Americas Hepato-Pancreato-Biliary Association being held in Miami, Florida on March 20-24, 2019. The poster will focus on data from its Phase II study of MS1819-SD in patients with chronic pancreatitis that was completed in 2018. “Our oral MS1819-SD therapy is a novel treatment for patients with gastrointestinal disorders and, based on these encouraging and positive data, we are continuing to progress our clinical trials.  We are currently enrolling patients in our cystic fibrosis study, which has 10 U.S. sites initiated to date with the rest expected to be up and running in the next four weeks.

  • GlobeNewswire2 months ago

    AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today provided a clinical development and strategic corporate update.

  • What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
    Simply Wall St.3 months ago

    What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?

    If you want to know who really controls AzurRx BioPharma, Inc. (NASDAQ:AZRX), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...

  • GlobeNewswire4 months ago

    AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has initiated the Company's Phase II OPTION study to investigate MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). The Phase II multi-center study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head comparison against the current porcine enzyme replacement therapy standard of care.  Planned enrollment is expected to include approximately 30 CF patients, with study completion anticipated in 2019.

  • GlobeNewswire4 months ago

    AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced that it is acquiring royalty and milestone obligations to its lead drug candidate MS1819-SD, a recombinant lipase for exocrine pancreatic insufficiency, from Protea Biosciences Group (“Protea”), who initiated Chapter 11 proceedings in December 2017. Following an auction held on November 27, 2018, AzurRx emerged as the successful bidder for contractual rights to milestone and royalty payments under a Stock Purchase and Sale Agreement previously executed by AzurRx and Protea.

  • Zacks Small Cap Research5 months ago

    AZRX: 3Q:18 Financial and Operational Summary

    Highlights for the period and to date include participation in investment conferences, presentation of favorable trial data, acceptance of a new IND and a nod of approval from the Therapeutics Development Network for their cystic fibrosis trial protocol. Financial results for the quarter reflect the interim between the chronic pancreatitis study and the cystic fibrosis study and show an expected dip in cash burn. Research and development expenses were up 21% compared to the prior year period as AzurRx established its R&D function in the United States and recognized related costs, but were down sequentially, representing a break between the CP and CF studies.

  • GlobeNewswire5 months ago

    AzurRx BioPharma to Present at Upcoming Investor Conferences

    BROOKLYN, N.Y., Dec. 04, 2018 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant.

  • GlobeNewswire6 months ago

    AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI

    On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019  NEW YORK, Nov. 01, 2018 -- AzurRx BioPharma, Inc..

  • Zacks Small Cap Research7 months ago

    AZRX: Final Results from Phase II EPI Trial

    Other endpoints were also positive, including Bristol stool scale, number of daily evacuations and weight of stool, which were consistent with the CFA results. CMO Dr. Pennington was pleased at the high level of statistical significance of the results and announced his expectation that the Phase IIb portion of the trial in cystic fibrosis (CF) will begin later in 2018. This compares to the dose response of just over 16% that was achieved in the Phase 1/2a FLIP110 study.

  • Zacks Small Cap Research8 months ago

    AZRX: Phase 2 Cystic Fibrosis Study to Start

    The company’s most important announcement year to date has been the completion of the Phase 2a trial for MS1819 in late June. Trial results were favorable and provided evidence of safety and efficacy for the Yarrowia lipolytica-derived lipase in exocrine pancreatic insufficiency (EPI). The company also raised $10 million in a public offering underwritten by Oppenheimer.

  • Zacks Small Cap Research10 months ago

    AZRX: AzurRx Announces Completion of Phase 2a MS1819 Trial

    AzurRx BioPharma, Inc. (AZRX) announced the completion of the Phase IIa MS1819-SD trial on June 29, 2018 and expects to provide a formal report presenting the data in the fall of 2018 at an as yet unidentified scientific conference. As a reminder, the trial was a Phase 2a open-label, dose escalation study conducted in France, Australia and New Zealand with the goal of identifying the safety of escalating doses and dose response. It was conduted in conjuntion with Mayoly Spindler Laboratories and launched November 17, 2016.

  • Zacks Small Cap Researchlast year

    AZRX: AzurRx Raises Capital After Confirming Results

    AzurRx BioPharma, Inc. (AZRX) provided an update regarding its Phase 2a trial for MS1819 for treatment of chronic pancreatic insufficiency (EPI) The April 23rd release identified consistent progress in the Phase 2a trial for MS1819 with respect to patient enrollment, safety and dose response. The trial is targeting 12 – 15 patients and is enrolling in France, Australia and New Zealand. Current screening and enrollment trends are on track for a 1H:18 study completion.

  • Benzingalast year

    Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...